CXCL10 and cancer: However, cancer cells can exploit the MAPK/ERK ‎pathway to modulate CXCL10 and the immune microenvironment in a manner that promotes ‎tumor evasion and metastasis, complicating therapeutic strategies to inhibit tumor growth.31